Skip to main content

tavalisse

Generic: fostamatinib disodium hexahydrate·Code: R788

tavalisse: developed by 1 company · 1 FDA decision.

tavalisse evidence translation

What we can confirm

What it means

Source-backed records connect tavalisse to RIGL; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could tavalisse → RIGL affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

chronic immune thrombocytopenia (ITP)

Study sponsors

No additional listed-company sponsor is linked.

Development Pipeline (1)
CompanyPhase
RIGEL PHARMACEUTICALS INC (RIGL)
chronic immune thrombocytopenia (ITP)
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. TAVALISSE is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.(RIGL)FDA ↗
NDA209299Type 1 - New Molecular EntityOrphan DrugStandardOralTablet

Frequently asked questions

Who is developing tavalisse?

tavalisse is being developed by RIGEL PHARMACEUTICALS INC.

What is tavalisse's latest FDA decision?

The most recent tracked FDA decision for tavalisse is Approval for 1 INDICATIONS AND USAGE TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. TAVALISSE is a kinase inhibitor indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment., dated April 17, 2018.